NHS-IL2 combined with SBRT had acceptable safety and tolerability, and demonstrated disease control in heavily pretreated patients with advanced melanoma who failed ipilimumab +/- anti-PD1 without the toxicities often associated with IL-2 treatment. This evidence concerns the gene RPL17 and melanoma.